Page 24 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Progress in the research of pathology and therapy in liver fibrosis

doi: 10.1038/srep44754 patients with primary biliary cholangitis. Clin Gastroenterol
Hepatol. 2020;18(5):1170-1178.e6.
74. Tsukahara Y, Ferran B, Minetti ET, et al. Administration
of glutaredoxin-1 attenuates liver fibrosis caused by aging doi: 10.1016/j.cgh.2019.09.050
and non-alcoholic steatohepatitis. Antioxidants (Basel).
2022;11(5):867. 85. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid
for the treatment of non-alcoholic steatohepatitis: Interim
doi: 10.3390/antiox11050867 analysis from a multicentre, randomised, placebo-controlled
75. Chen G, Ni Y, Nagata N, et al. Pirfenidone prevents and reverses phase 3 trial. Lancet. 2019;394(10215):2184-2196.
hepatic insulin resistance and steatohepatitis by polarizing M2 doi: 10.1016/S0140-6736(19)33041-7
macrophages. Lab Invest. 2019;99(9):1335-1348.
86. Rinella ME, Dufour JF, Anstee QM, et al. Non-invasive
doi: 10.1038/s41374-019-0255-4 evaluation of response to obeticholic acid in patients with
76. Xi Y, Li Y, Xu P, et al. The anti-fibrotic drug pirfenidone NASH: Results from the REGENERATE study. J Hepatol.
inhibits liver fibrosis by targeting the small oxidoreductase 2022;76(3):536-548.
glutaredoxin-1. Sci Adv. 2021;7(36):eabg9241. doi: 10.1016/j.jhep.2021.10.029
doi: 10.1126/sciadv.abg9241 87. Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a
77. Armendáriz-Borunda J, Islas-Carbajal MC, Meza-García E, Nonsteroidal FXR agonist, in patients with noncirrhotic
et al. A pilot study in patients with established advanced NASH: A phase 2 randomized controlled trial. Hepatology.
liver fibrosis using pirfenidone. Gut. 2006;55(11):1663-1665. 2020;72(1):58-71.
doi: 10.1136/gut.2006.107136 doi: 10.1002/hep.31205
78. Flores-Contreras L, Sandoval-Rodríguez AS, Mena- 88. Ratziu V, Harrison SA, Loustaud-Ratti V, et al. Hepatic
Enriquez MG, et al. Treatment with pirfenidone for two and renal improvements with FXR agonist vonafexor
years decreases fibrosis, cytokine levels and enhances CB2 in individuals with suspected fibrotic NASH. J Hepatol.
gene expression in patients with chronic hepatitis C. BMC 2023;78:479-492.
Gastroenterol. 2014;14:131. doi: 10.1016/j.jhep.2022.10.023
doi: 10.1186/1471-230X-14-131 89. Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E.
79. Sandoval-Rodriguez A, Monroy-Ramirez HC, Meza- Bile acid modulators for the treatment of nonalcoholic
Rios A, et al. Pirfenidone is an agonistic ligand for PPARα steatohepatitis (NASH). Expert Opin Investig Drugs.
and improves NASH by activation of SIRT1/LKB1/pAMPK. 2020;29(6):623-632.
Hepatol Commun. 2020;4(3):434-449. doi: 10.1080/13543784.2020.1763302
doi: 10.1002/hep4.1474 90. Siddiqui MS, Van Natta ML, Connelly MA, et al. Impact of
80. Poo JL, Torre A, Aguilar-Ramírez JR, et al. Benefits of obeticholic acid on the lipoprotein profile in patients with
prolonged-release pirfenidone plus standard of care non-alcoholic steatohepatitis. J Hepatol. 2020;72(1):25-33.
treatment in patients with advanced liver fibrosis: doi: 10.1016/j.jhep.2019.10.006
PROMETEO study. Hepatol Int. 2020;14(5):817-827.
91. Pockros PJ, Fuchs M, Freilich B, et al. CONTROL:
doi: 10.1007/s12072-020-10069-3 A randomized phase 2 study of obeticholic acid and
81. Nevens F, Andreone P, Mazzella G, et al. A Placebo- atorvastatin on lipoproteins in nonalcoholic steatohepatitis
controlled trial of obeticholic acid in primary biliary patients. Liver Int. 2019;39(11):2082-2093.
cholangitis. N Engl J Med. 2016;375(7):631-643. doi: 10.1111/liv.14209
doi: 10.1056/NEJMoa1509840 92. Wang Y, Nakajima T, Gonzalez FJ, Tanaka N. PPARs as
82. Kowdley KV, Luketic V, Chapman R, et al. A randomized trial metabolic regulators in the liver: Lessons from liver-specific
of obeticholic acid monotherapy in patients with primary PPAR-null mice. Int J Mol Sci. 2020;21(6):2061.
biliary cholangitis. Hepatology. 2018;67(5):1890-1902. doi: 10.3390/ijms21062061
doi: 10.1002/hep.29569 93. Musso G, Cassader M, Paschetta E, Gambino R.
83. Kowdley KV, Vuppalanchi R, Levy C, et al. A randomized, Thiazolidinediones and advanced liver fibrosis in
placebo-controlled, phase II study of obeticholic acid for nonalcoholic steatohepatitis: A meta-analysis. JAMA Intern
primary sclerosing cholangitis. J Hepatol. 2020;73(1):94-101. Med. 2017;177(5):633-640.
doi: 10.1016/j.jhep.2020.02.033 doi: 10.1001/jamainternmed.2016.9607
84. Bowlus CL, Pockros PJ, Kremer AE, et al. Long-term 94. Kumar DP, Caffrey R, Marioneaux J, et al. The PPAR
obeticholic acid therapy improves histological endpoints in α/γ agonist saroglitazar improves insulin resistance

Volume 9 Issue 3 (2025) 16 doi: 10.36922/ejmo.8125